A handful of Chinese biotechnology companies are expected to bring medications to consumers in Europe and the US under their own brand names within the next 10 to 15 years, according to policy and industry analysts. Amid China’s early-stage drug outlicensing boom, discussions have arisen among investor and analyst circles as to when – and which – Chinese biotechnology companies will start selling their own drugs internationally. Outlicensing agreements typically refer to a company granting...
Scientists in China are growing towering hybrids of wheat and rye – taller even than some humans – in the deserts of its western Xinjiang region. The hybrids, known as triticale, can adapt more easily than wheat to challenging conditions and, in addition to providing food for humans, their stalks and leaves can be used for animal feed. “It is tolerant of poor soil, cold, drought, salinity, and wind and sand,” Kuang Feiting, the executive director of Xinjiang Maishengdao Biotechnology, the firm...
Home-grown innovative drugs make up most of the medicines China’s drug regulator has approved for sale so far this year, underscoring the country’s biotech boom. Of the 19 innovative drugs cleared by the National Medical Products Administration (NMPA), 15 came from domestic companies, according to the regulator’s website as of May 21. These include sonrotoclax, developed by global biopharmaceutical firm BeOne, for treating certain adult blood cancers. The regulator overhauled its approval...
China ranked third in a new global index measuring competitiveness in AI for biotechnology, healthcare and longevity, as the race to apply AI moves from chatbots and general-purpose models into regulated, data-heavy industries such as drug discovery, diagnostics and preventive medicine. The latest edition of the Global AI Competitiveness Index, released on Monday by Deep Knowledge Group, a consortium focused on deep-tech research, analytics and investment, ranked China behind only the US and UK...